Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Thitima Kongnakorn,1 Murtuza Bharmal,2 Mairead Kearney,3 Hemant Phatak,4 Agnes Benedict,5 Abhijeet Bhanegaonkar,4 Matthew Galsky6 1Evidence Synthesis, Modeling and Communication, Evidera, London, UK; 2Global Evidence and Value Development, EMD Serono, Inc. (A business of Merck KGaA, Darmstadt, Germa...

Full description

Bibliographic Details
Main Authors: Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M
Format: Article
Language:English
Published: Dove Medical Press 2019-11-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
urothelial carcinoma
budget impact model
cost analysis
economic analysis
immuno-oncology
chemotherapy
Online Access:https://www.dovepress.com/budget-impact-of-including-avelumab-as-a-second-line-treatment-for-loc-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/budget-impact-of-including-avelumab-as-a-second-line-treatment-for-loc-peer-reviewed-article-CEOR

Similar Items